MoonLake Immunotherapeutics' Lead Program – Sonelokimab

By Hao Liu • Monday, August 10 10:57 • Permanent Link

MoonLake Immunotherapeutics recently released its 10-Q report. The company is a clinical-stage biotechnology firm focused on therapies for inflammatory skin and joint diseases. Its lead program is sonelokimab, a tri-specific IL-17A and IL-17F inhibiting Nanobody being studied in dermatology and rheumatology, including hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis and psoriasis. Founded in 2021 and based in Zug, Switzerland, the company remains centered on advancing this single platform candidate.

In Item 2, Management’s Discussion and Analysis, MoonLake says the discussion should be read together with its unaudited condensed consolidated financial statements for the six months ended June 30, 2026 and its audited 2025 annual financial statements. The company states that the interim financial statements were prepared under U.S. GAAP and presented in U.S. dollars, and it uses “MoonLake,” “we,” “us,” “our,” and similar terms to refer to MoonLake Immunotherapeutics and its consolidated subsidiaries. Following these announcements, the company's shares moved -5.42%, and are now trading at a price of $17.27. If you want to know more, read the company's complete 10-Q report here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.